U.S. Diversified Financial Stock News

Mueller Industries stock caught attention after management highlighted steady performance despite a slowdown in residential construction and extra imports ahead of tariffs. The company’s recent 25% dividend increase, their fifth consecutive year of growth, underscores ongoing confidence. See our latest analysis for Mueller Industries. Mueller Industries’ momentum has been clear, with the stock climbing 22.8% in the past three months and delivering a stellar 28.1% total shareholder return over...

DexCom (DXCM) delivered impressive third-quarter numbers, showing sales and profit growth while lifting its 2025 revenue guidance to about 15% higher. The company’s solid report was quickly followed by a more subdued long-term outlook. See our latest analysis for DexCom. Despite beating expectations with sharp sales and profit growth, DexCom’s share price has tumbled, falling more than 8% after earnings and posting a 1-year total shareholder return of -11.3%. Concerns over sensor reliability,...

Sun West Mortgage Co. has filed a lawsuit against First National Bank of Pennsylvania, a subsidiary of F.N.B (FNB), regarding claims tied to a 2017 settlement related to reverse mortgages. This legal action raises important questions for FNB shareholders about financial exposure and reputational impact. See our latest analysis for F.N.B. While attention is focused on the new lawsuit, it is worth noting that F.N.B has also earned multiple Top Workplaces awards again this year, confirming its...

Wondering if JinkoSolar Holding’s current share price really reflects its value? You’re not alone, and we’re about to unpack just how much the market might be getting it right or wrong. JinkoSolar’s stock has jumped 10% in the last week, barely moved over the last month, and is still down 6.5% over the past year. This suggests that investor sentiment may be shifting, but underlying risks or opportunities remain in play. Recent headlines have focused on the global solar industry’s evolving...

PJT Partners (PJT) posted a net profit margin of 10.7%, up from 8% last year, signaling improved profitability. Earnings are on a tear, with annual growth hitting 64.9%, far exceeding the firm’s 5-year average of 6.4% per year and pointing to a period of rapid acceleration. Despite this robust earnings momentum, analysts expect future earnings to contract by 2.8% per year while revenue growth is forecast at 8.6%, trailing the broader US market’s 10.5% pace. This may lead investors to...

LendingClub (LC) shares have climbed about 20% over the past month after a stretch of mixed trading. The recent gains come amid gradually improving revenue growth and a sharp year-over-year rise in net income, which is up nearly 38%. See our latest analysis for LendingClub. Momentum appears to be building for LendingClub, with a 1-month share price return of 20% pushing its shares up to $17.76. This recent surge follows a period of choppy trading. Zooming out, investors have enjoyed a total...

Kura Oncology (KURA) remains unprofitable and is projected to stay in the red for at least the next three years, with losses having widened at a pace of 15.3% per year over the last five. Despite negative profit margins and no signs of bottom-line improvement, the company is forecast to deliver revenue growth of 42.7% annually, significantly outpacing the broader US market’s 10.5% revenue growth expectation. Investors now face a trade-off between robust top-line growth potential and the...

Wondering if BioMarin Pharmaceutical is a hidden gem or an opportunity that's passed you by? Let's dig into what we can actually learn from the data, especially if you're curious about whether it looks undervalued right now. The stock has seen some notable downside lately, dropping 5.2% over the last month and 21.0% year-to-date. This could signal changing risk perceptions or even a potential bargain. Market sentiment recently cooled after regulatory developments in the rare disease space...

Axsome Therapeutics (AXSM) shares have delivered a steady run lately, climbing 12% over the past month and up more than 50% this year. Investors are considering how current momentum relates to company performance and future prospects. See our latest analysis for Axsome Therapeutics. Momentum has clearly been building for Axsome Therapeutics, with the share price up over 54% year-to-date and the 1-year total shareholder return exceeding 51%. This sustained outperformance suggests growing...

AeroVironment (AVAV) just announced a new collaboration with OpenJAUS to integrate the JAUS standard into its AV_Halo Command platform. This move provides streamlined and unified control to uncrewed systems across manufacturers, making it easier for defense operators to manage complex platforms. See our latest analysis for AeroVironment. After integrating the JAUS standard with AV_Halo Command, AeroVironment continues to build momentum, fresh off a $95.9 million Army contract for its LRKI...

ONE Gas (OGS) reported net profit margins of 10.8%, slightly ahead of last year’s 10.5%, as annual earnings growth reached 17.7%, substantially outpacing the company’s five-year average of 4.5%. Earnings are forecast to grow at 8.94% per year, but both profit and revenue trends remain below broader US market averages. Investors will note that despite stronger bottom-line results, valuation appears mixed given that the stock’s Price-to-Earnings ratio sits between its US and global gas utility...

Wondering if ONEOK might be a hidden value in the energy sector? Let’s dig into whether the numbers back up that gut feeling, especially if you are looking for opportunities others might have missed. The stock has had a rough patch recently, sliding 6.9% over the past week and 11.8% over the last month, with a year-to-date drop of 36.8% and a one-year loss of 31.4%. Looking at a longer timeline, over five years shares are still up an impressive 164.5%. Some of the recent price movement...

Merck recently announced an agreement to receive US$700 million in funding from Blackstone Life Sciences to advance the development of sacituzumab tirumotecan, an investigational cancer therapy, in exchange for future royalties contingent on regulatory approval and successful clinical trial outcomes. This partnership allows Merck to accelerate innovation while retaining full control over development and commercialization of the candidate. The collaboration with Blackstone underscores...

SEI Investments (SEIC) just reported higher revenue and net income for the third quarter, highlighting ongoing business momentum. At the same time, Clermont Trust USA became the latest client to adopt the SEI Wealth Platform. See our latest analysis for SEI Investments. Momentum seems to be building for SEI Investments, with the recent Clermont Trust USA win and ongoing buybacks bringing attention to its steady business expansion. The stock’s latest share price is $81.64, and while...

Wondering if Western Digital’s rapid rise means it’s still a bargain, or if you’ve already missed the boat? Let’s break down what’s really driving interest in this tech stock right now. Western Digital’s share price has soared, up 21.8% over the last week, another 15.9% in the past month, and an incredible 202.3% in the past year. This hints at both strong momentum and possibly shifting risk perceptions among investors. Recent headlines about Western Digital’s strategic positioning in AI...

Recent analysis has highlighted Archer Aviation's asset-light manufacturing strategy and its focus on both commercial air taxi and defense markets. This approach, combined with a substantial cash position and an identified route towards profitability, is increasing Archer's distinction among its sector peers. Let's look at how the company's focus on upside potential and a clear path to profitability shapes Archer's investment narrative. We've found 20 US stocks that are forecast to pay a...

Harmony Biosciences Holdings (HRMY) delivered a net profit margin of 22.5% this period, well above last year's 18%. Earnings grew by 51.4% over the past year, outpacing both its own five-year average growth rate of 40.8% and broader US market expectations. Looking ahead, analysts forecast earnings to grow 20.5% per year, surpassing the US market's 16%, while revenue is expected to rise at 12.7% annually compared to the market's 10.5% pace. This combination of sustained profitability and...

Chewy has raised its Chewy+ membership fee from US$49 to US$79, reflecting management’s confidence in the premium program’s value proposition and positioning for increased revenue potential. This move, paired with sustained positive analyst sentiment, highlights the company’s emphasis on recurring revenue streams and its continued momentum with both investors and customers. We'll examine how Chewy's increase in Chewy+ membership fee could influence the company’s growth outlook and investment...

On November 3, 2025, Prelude Therapeutics announced a private placement, raising US$25,000,000 by issuing 6,250,000 shares at US$4 each, with participation from Incyte Corporation. Institutional interest from a company like Incyte can be viewed as an endorsement of Prelude’s research direction and funding outlook. We’ll explore how Incyte’s involvement in the private placement shapes Prelude’s investment narrative and financial flexibility. The best AI stocks today may lie beyond giants like...

Hecla Mining (HL) shares have seen a modest bump this month, with the stock up just under 1%. Investors are keeping a close eye on how its performance lines up with broader trends in the metals sector. See our latest analysis for Hecla Mining. Hecla Mining’s share price may have treaded water over the past month, but the real story is its eye-catching 96% gain over the last three months and a year-to-date share price return of 128%. With metals prices in focus and sector momentum building,...

Expeditors International of Washington (EXPD) reported a net profit margin of 7.6%, up from 7.4% a year ago, signaling a modest expansion in profitability. Earnings grew 15.4% over the past year. However, the longer-term five-year trend shows a decline of 6% per year. Looking ahead, analysts expect earnings to decline by 1.1% annually over the next three years, along with minimal revenue growth of 0.2% per year. This trails well behind the broader US market's projected 10.5% annual rate. The...

Collegium Pharmaceutical (COLL) has shown steady gains over the past month, with the stock advancing 3% and building on its momentum from the past 3 months, where returns top 20%. This trend has caught the attention of many investors. See our latest analysis for Collegium Pharmaceutical. After a sustained climb over the past quarter, Collegium Pharmaceutical’s 20.2% 3-month share price return has helped drive a more robust year-to-date move. However, the 1-year total shareholder return is a...

Glacier Bancorp, Inc. recently filed a shelf registration, allowing it to issue various securities such as common and preferred stock, depositary shares, debt securities, warrants, rights, and units in the future. This new shelf registration offers the company increased flexibility to strengthen its capital base as it pursues further growth and manages industry uncertainties. We’ll examine how this expanded funding capability could influence Glacier Bancorp’s investment narrative and future...

TransMedics Group reported strong third quarter financial results, with revenue for the period ending September 30, 2025 reaching US$143.82 million and net income of US$24.32 million. The company also raised its full-year 2025 revenue guidance mid-point, reflecting management's confidence in ongoing adoption of its transplant technology across key markets. We’ll explore how TransMedics’ upgraded revenue outlook may influence analyst expectations for the company’s longer-term earnings...